An Investigation of ReNu™ Knee Injection in Patients With Osteoarthritis
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02318511 |
Recruitment Status :
Completed
First Posted : December 17, 2014
Last Update Posted : January 18, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Osteoarthritis | Procedure: Knee injection Other: ReNu amniotic allograft Device: placebo saline Device: Hyaluronic Acid | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 200 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Single (Participant) |
Primary Purpose: | Treatment |
Official Title: | An Investigation of ReNu™ Knee Injection: Monitoring the Response of Knee Function and Pain in Patients With Osteoarthritis |
Study Start Date : | June 2015 |
Actual Primary Completion Date : | January 2019 |
Actual Study Completion Date : | February 2019 |

Arm | Intervention/treatment |
---|---|
Experimental: ReNu amniotic allograft
Knee injection with ReNu. ReNu is an allograft tissue composed of particularized amniotic membrane and cell from the amniotic fluid.
|
Procedure: Knee injection
Injection into knee for the treatment of Osteoarthritis Other: ReNu amniotic allograft |
Placebo Comparator: Saline
Knee injection with saline. Injectable saline will be used as the placebo control.
|
Procedure: Knee injection
Injection into knee for the treatment of Osteoarthritis Device: placebo saline |
Active Comparator: HA injection
Knee injection with HA. HA will be used as a viscosupplementation injection consisting of cross linked HA.
|
Procedure: Knee injection
Injection into knee for the treatment of Osteoarthritis Device: Hyaluronic Acid |
- VAS Pain Scale Change from Baseline [ Time Frame: 3 months ]
- VAS Pain Scale Change from Baseline [ Time Frame: 6 months ]
- KOOS Pain and Function Subscales Change from Baseline [ Time Frame: 3 months ]
- KOOS Pain and Function Subscales Change from Baseline [ Time Frame: 6 months ]
- KOOS Pain and Function Subscales change from Baseline [ Time Frame: 1 week, 6 weeks, 3 months, and 12 months ]
- Other patient reported outcomes (PROs) change from Baseline [ Time Frame: 1 week, 6 week, 3 months, 6 months, and 12 months ]
- Radiographic (X-ray) measurement of standing joint space change from Baseline [ Time Frame: 12 months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Patients with moderate knee osteoarthritis determined by a combination of clinical and radiographic findings and documented by Kellgren-Lawrence radiographic classification (Grade 2 or 3)
- Grade 2 Kellgren-Lawrence radiographic changes are defined as small osteophytes, possible narrowing of joint space
- Grade 3 Kellgren-Lawrence radiographic changes are defined as moderate multiple osteophytes, definite narrowing of joints space, some sclerosis and possible deformity of bone contour.
- Patients with bilateral grade 2 or 3 Kellgren Lawrence knee osteoarthritis who have bilateral symptoms may have their more symptomatic knee injected. If equivalent symptoms are reported by the patient, then the patient will choose which knee is to be injected. The contralateral knee can be treated with local standard of care such as steroid injection, cold therapy or soft brace.
- Age 18 and older
- BMI less than 40
- 7 day average pain score of 4 or greater for the involved knee on a numeric pain scale from 1 to 10.
- Female patients must be actively practicing a contraception method, abstinence, be surgically sterilized, or be postmenopausal
Exclusion Criteria:
- Pain medication (including nonsteroidal antiinflammatory drugs, NSAIDs) less than 15 days before injection (may take acetaminophen)
- Receiving pain medication other than acetaminophen for conditions unrelated to osteoarthritis of the index knee
- Regular use of anticoagulants, such as Coumadin, dabigatran or rivaroxaban; use of antiplatelet medications are not a reason for exclusion
- History of substance abuse.
- Failure to agree NOT to take additional knee symptom modifying drugs, other than acetaminophen, during the course of the study without reporting to the study team
- Pregnancy or desire to become pregnant during study duration
- Positive pregnancy test on premenopausal subject
- Morbid obesity (defined as BMI 40 or greater)
- Symptoms of locking, intermittent block to range of motion or loose body sensation which could indicate meniscal displacement or an intraarticular loose body
- Corticosteroid injection into the index knee within 3 months
- Viscosupplement injection into the index knee within 3 months
- Knee surgery of involved index knee within 12 months
- Knee surgery contralateral knee 6 months
- Worker compensation
- Acute index knee injury (injury within 3 months)
- History of Diabetes mellitus
- History of solid organ or hematologic transplantation
- History of rheumatoid arthritis or other autoimmune disorder
- Diagnosis of a non-basal cell malignancy within the preceding 5 years
- Infection requiring antibiotic treatment within the preceding 3 months
- Current therapy with any immunosuppressive medication, including corticosteroids at a dose > 5 mg per day

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02318511
United States, Alabama | |
American Sports Medicine Institute | |
Birmingham, Alabama, United States, 35205 | |
United States, California | |
Cedars-Sinai Medical Center | |
Los Angeles, California, United States, 90048 | |
United States, Illinois | |
Midwest Orthopedics at Rush, LLC | |
Chicago, Illinois, United States, 60612 | |
United States, Indiana | |
Orthoindy | |
Indianapolis, Indiana, United States, 46143 | |
United States, Kentucky | |
Center for Clinical and Translational Science UK Chandler Medical Center, Pavilion H | |
Lexington, Kentucky, United States, 40536-2093 | |
United States, Massachusetts | |
Brigham and Women's Hospital | |
Chestnut Hill, Massachusetts, United States, 02467 | |
United States, Missouri | |
Missouri Orthopaedic Institute (MOI) | |
Columbia, Missouri, United States, 65212 | |
United States, New Mexico | |
New Mexico Orthopaedics | |
Albuquerque, New Mexico, United States, 87106 | |
United States, New York | |
New York University | |
New York, New York, United States, 10003 | |
Hospital for Special Surgery | |
New York, New York, United States, 10021 | |
United States, Ohio | |
The Ohio State University | |
Columbus, Ohio, United States, 43221 | |
United States, Virginia | |
Advanced Orthopedics | |
Richmond, Virginia, United States, 23294 |
Principal Investigator: | Jack Farr, MD | OrthoIndy |
Responsible Party: | NuTech Medical, Inc |
ClinicalTrials.gov Identifier: | NCT02318511 |
Other Study ID Numbers: |
RD2014-10-04 |
First Posted: | December 17, 2014 Key Record Dates |
Last Update Posted: | January 18, 2020 |
Last Verified: | January 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Osteoarthritis Arthritis Joint Diseases Musculoskeletal Diseases Rheumatic Diseases Hyaluronic Acid |
Adjuvants, Immunologic Immunologic Factors Physiological Effects of Drugs Viscosupplements Protective Agents |